Versican Secreted by Cancer-Associated Fibroblasts is a Poor Prognostic Factor in Hepatocellular Carcinoma

[1]  T. Cox.  The matrix in cancer , 2021, Nature Reviews Cancer.

[2]  M. Osanai,et al.  Aberrant expression of junctional adhesion molecule‐A contributes to the malignancy of cervical adenocarcinoma by interaction with poliovirus receptor/CD155 , 2020, Cancer science.

[3]  F. Mechta-Grigoriou,et al.  Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies. , 2020, Seminars in immunology.

[4]  B. C. Jena,et al.  Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[5]  F. Asimakopoulos,et al.  Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity , 2020, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  M. Osanai,et al.  Aldolase A promotes epithelial‐mesenchymal transition to increase malignant potentials of cervical adenocarcinoma , 2020, Cancer science.

[7]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[8]  I. Kang,et al.  Versican—A Critical Extracellular Matrix Regulator of Immunity and Inflammation , 2020, Frontiers in Immunology.

[9]  R. Jain,et al.  A framework for advancing our understanding of cancer-associated fibroblasts , 2020, Nature Reviews Cancer.

[10]  F. Asimakopoulos,et al.  Versican in the Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.

[11]  T. Andl,et al.  Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment , 2019, Front. Cell Dev. Biol..

[12]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[13]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[14]  D. Siemann,et al.  Stromal cells in breast cancer as a potential therapeutic target , 2018, Oncotarget.

[15]  A. Said,et al.  Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma , 2017, World journal of clinical oncology.

[16]  G. Ioannou,et al.  HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. , 2017, Journal of hepatology.

[17]  P. Gascard,et al.  Carcinoma-associated fibroblasts: orchestrating the composition of malignancy , 2016, Genes & development.

[18]  C. Tiribelli,et al.  The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis , 2015, BMC Cancer.

[19]  V. Weaver,et al.  The extracellular matrix modulates the hallmarks of cancer , 2014, EMBO reports.

[20]  Y. Nie,et al.  Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression , 2014, Hepatology.

[21]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[22]  Jinsong Liu,et al.  TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. , 2013, Cancer research.

[23]  Dan Theodorescu,et al.  RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. , 2012, The Journal of clinical investigation.

[24]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[25]  Anna Marco-Ramell,et al.  Role of versican V0/V1 and CD44 in the regulation of human melanoma cell behavior. , 2011, International journal of molecular medicine.

[26]  A. Hongo,et al.  Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. , 2010, Oncology reports.

[27]  S. Todo,et al.  Recurrence Patterns After Hepatectomy of Hepatocellular Carcinoma: Implication of Milan Criteria Utilization , 2009, Annals of Surgical Oncology.

[28]  A. Hongo,et al.  Versican expression in human cervical cancer. , 2007, European journal of cancer.

[29]  A. Hongo,et al.  Prognostic significance of stromal versican expression in human endometrial cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[31]  V. Kosma,et al.  Versican in epithelial ovarian cancer: Relation to hyaluronan, clinicopathologic factors and prognosis , 2003, International journal of cancer.

[32]  Zenzo Isogai,et al.  Versican Interacts with Fibrillin-1 and Links Extracellular Microfibrils to Other Connective Tissue Networks* , 2002, The Journal of Biological Chemistry.

[33]  D Heinegård,et al.  The Proteoglycans Aggrecan and Versican Form Networks with Fibulin-2 through Their Lectin Domain Binding* , 2001, The Journal of Biological Chemistry.

[34]  R. Iozzo.  Matrix proteoglycans: from molecular design to cellular function. , 1998, Annual review of biochemistry.

[35]  E. Ruoslahti,et al.  The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .